Spyglass Pharma, INC

SpyGlass Pharma reported Q1 2026 financial results, highlighting positive Phase 1/2 data for its BIM-IOL System and strong cash reserves.

SpyGlass Pharma reports positive Phase 1/2 BIM-IOL data, successful $172.5M IPO, and extended cash runway through 2028, despite increased net losses in 2025.

SpyGlass Pharma's Compensation Committee approved performance cash bonuses for its Named Executive Officers for Fiscal Year 2025, updating previously undisclosed compensation figures.

SpyGlass Pharma, Inc. announced the successful closing of its initial public offering, raising $172.5 million, and the appointment of Habib Dable to its board of directors.

SpyGlass Pharma, Inc. reported its first-quarter 2026 financial results, highlighting progress in its Phase 3 clinical trials for the BIM-IOL System aimed at treating glaucoma.

SpyGlass Pharma, Inc. reports significant progress in its BIM-IOL System for glaucoma, initiating two Phase 3 clinical trials and completing a successful IPO in early 2026, despite ongoing financial losses.

RA Capital Management and its affiliated funds significantly increased their beneficial ownership in SpyGlass Pharma, Inc. through preferred stock conversion and a substantial common stock purchase at $16 per share following the company's IPO.

Kirk G. Nielsen, a director of SpyGlass Pharma, Inc., filed an amended Form 4 to correct reported beneficial ownership following preferred stock conversion.

SpyGlass Pharma Director and 10% owner Ali Behbahani reported significant acquisitions of common stock, including a direct purchase and conversions of preferred shares, following the company's IPO.

A director and 10% owner of SpyGlass Pharma, Scott D. Sandell, reported the automatic conversion of preferred stock into common stock and a significant common stock purchase coinciding with the company's initial public offering.

Director and 10% owner Carmen Chang reported significant acquisitions of SpyGlass Pharma common stock, primarily through preferred stock conversions and a direct purchase, coinciding with the company's IPO.

Edward T. Mathers, a director and 10% owner of SpyGlass Pharma, Inc., significantly increased his indirect beneficial ownership to over 6 million common shares through conversions and a direct purchase.

New Enterprise Associates funds and their managers have filed a Schedule 13D, revealing a significant 22.2% beneficial ownership in SpyGlass Pharma, Inc. following its recent IPO.

Vensana Capital I, L.P. and its affiliates have reported a 9.9% beneficial ownership stake in SpyGlass Pharma, Inc. following the company's initial public offering.

Sands Capital entities and Frank M. Sands have reported significant beneficial ownership in SpyGlass Pharma, Inc., with Frank M. Sands holding 7.8% of common stock.